277 related articles for article (PubMed ID: 33351178)
1. Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?
Wright E; Yasmeen N; Malottki K; Sawyer LM; Borg E; Schwenke C; Warren RB
Dermatol Ther (Heidelb); 2021 Feb; 11(1):181-220. PubMed ID: 33351178
[TBL] [Abstract][Full Text] [Related]
2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
3. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
4. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Warren RB; See K; Burge R; Zhang Y; Brnabic A; Gallo G; Garrelts A; Egeberg A
Dermatol Ther (Heidelb); 2020 Feb; 10(1):73-86. PubMed ID: 31686337
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
Ellis AG; Flohr C; Drucker AM
Br J Dermatol; 2019 Feb; 180(2):282-288. PubMed ID: 30347448
[TBL] [Abstract][Full Text] [Related]
7. Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
Fahrbach K; Sarri G; Phillippo DM; Neupane B; Martel SE; Kiri S; Reich K
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1965-1998. PubMed ID: 34549383
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Armstrong A; Fahrbach K; Leonardi C; Augustin M; Neupane B; Kazmierska P; Betts M; Freitag A; Kiri S; Taieb V; Slim M; Gomez NN; Warren RB
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1777-1792. PubMed ID: 35798920
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Stakias V; Puig L
Dermatol Ther (Heidelb); 2022 Jan; 12(1):167-184. PubMed ID: 34862951
[TBL] [Abstract][Full Text] [Related]
12. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
Mrowietz U; Warren RB; Leonardi CL; Saure D; Petto H; Hartz S; Dossenbach M; Reich K
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1161-1175. PubMed ID: 33480102
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
[TBL] [Abstract][Full Text] [Related]
14. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
Blauvelt A; Gooderham M; Griffiths CEM; Armstrong AW; Zhu B; Burge R; Gallo G; Guo J; Garrelts A; Lebwohl M
Dermatol Ther (Heidelb); 2022 Mar; 12(3):727-740. PubMed ID: 35195887
[TBL] [Abstract][Full Text] [Related]
15. Network meta-analyses in psoriasis: overview and critical discussion.
Augustin M; Valencia López M; Reich K
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2367-2376. PubMed ID: 34506643
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Yasmeen N; Sawyer LM; Malottki K; Levin LÅ; Didriksen Apol E; Jemec GB
J Dermatolog Treat; 2022 Feb; 33(1):204-218. PubMed ID: 32202445
[TBL] [Abstract][Full Text] [Related]
18. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Warren RB; Zhong Y; Zhuo J; Cichewicz A; Kadambi A; Junqueira D; Westley T; Kisa R; Daamen C; Augustin M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2839-2857. PubMed ID: 37801281
[TBL] [Abstract][Full Text] [Related]
19. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups.
Wade R; Sharif-Hurst S; Dias S
Syst Rev; 2020 Jun; 9(1):132. PubMed ID: 32503632
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
